IDWeek 2012

Ceftolozane/tazobactam has greater in vitro activity than ceftazidime, cefepime, and piperacillin/tazobactam when tested against P. aeruginosa and Enterobacteriaceae strains that cause pneumonia in U.S. hospitals, as seen in a study presented at IDWeek 2012.

In critically ill adult patients, extended infusion of meropenem correlates with a faster progression to death vs. intermittent infusion of the drug, as reported at IDWeek 2012.

For children with Staphylococcus aureus osteomyelitis, the presence of venous thromboembolism is associated with a higher C-reactive protein at admission, longer hospital stay, and ICU admission, according to Kavita Patel, MD, from Baylor College of Medicine and Texas Children’s Hospital, Houston, TX, at IDWeek 2012.

At IDWeek, studies showed ceftaroline plus avibactam has wide-ranging in vitro bactericidal activity against resistant acute bacterial skin and skin structure infections clinical isolates.

Virologic failure of second-line combination ART was less likely if patients were switched with an HIV RNA viral load (VL) <400c/mL, according to a study presented at IDWeek 2012.

Doses of daptomycin that are ≥10mg/kg may be a feasible option for the treatment of critical gram-positive infections, as reported at IDWeek 2012.

Vancomycin capsules and compounded oral solution do not differ in terms of patient outcomes in the treatment of severe C. difficile infection, according to a retrospective study presented at IDWeek 2012.

As presented at IDWeek 2012, the importance of clinical response at Day 4 in relation to hospital length of stay was demonstrated in two randomized controlled Phase 3 trials of patients who received ceftaroline fosamil and ceftriaxone for community-acquired pneumonia.

High exposure to other medications known to cause pancreatitis occurred prior to and concomitantly in tigecycline and comparator cases and non-cases of pancreatitis, according to a study presented at IDWeek 2012.

PCV 13, a 13-valent pneumococcal conjugate vaccine, showed a favorable safety profile and immunogenicity when administered concomitantly with DTaP, a report at at IDWeek 2012 demonstrated.